WVE · Wave Life Sciences, Inc.

Track WVE — free

$3.70 +0.06 (+1.65%) At close · Sep 30

Russell 2000 member Rebalance outlook locked

Market Cap

$744.84M

197.05M

Volume · Sep 30 4.21M Avg daily vol (3M) 3.05M

Up next

Next earnings call

Oct 25, 2026 Est · unconfirmed · in 3 wks

Latest filing: 10-Q

filed Jul 30, 2026

Q2 2026 earnings call transcript

call held Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

-48.9%

Trailing year

Short interest

9.0%

Latest settlement · 5.2 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −58%

below

Price vs 50-day avg −27%

below

RSI (14) 24

oversold

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −26%

trailing

6-month return −48%

trailing

YTD return −78%

this year

Relative strength −60%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $5 › 200d $9 — 200d above 50d

Institutional flow Accumulating

+3% holders QoQ · +50 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

8.95% of float · ▲ +8.3% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

242 holders — near 3-yr high, broad support

Squeeze score 64

elevated · 0–100

Fundamentals

Weak

Revenue growth +149%

Y/Y

EPS growth −73%

Y/Y

Free cash flow $-188.2M

Quant / Vol

risk profile

Very High

Volatility 168%

annualized · 1-yr

Max drawdown −83%

past year

ATR 6.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−58% Bearish

Price vs 50-day avg

−27% Bearish

RSI (14)

24 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $5 › 200d $9 — 200d above 50d

Institutional flow Accumulating

+3% holders QoQ · +50 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

8.95% of float · ▲ +8.3% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

242 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $4 Now $4 · 0% Range high $21

vs 200-day avg -58% vs 50-day avg -27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
WVE Wave Life Sciences, Inc. this stock	$744.84M	-78.2%	+149.4%	—	9.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+15.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-1.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+553.0%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

242

% held: 93.0%
Net QoQ: +5.8M sh
Top holder: RA CAPITAL MANAGEMENT, L.…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

17.6M

Days to cover: 5.2d
Change: +1.4M sh

View

Short Volume

Short vol %

28%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $78
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

43.2%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$42.7M

Net income (FY): $-204.4M
EPS diluted: $-1.21

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Aug 12, 2026
This year: 18

View

Proposed Sales

Value

$64.1K

Shares: 12.7K
Filed: Aug 12, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 12, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
WVE	-6.3%	-25.6%	-48.3%	-24.5%	-78.2%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	-5.7%	-25.7%	-60.5%	-23.9%	-90.1%

Key facts CIK 1631574 CUSIP 94352A104 13F (30d) 4 filings 4 filers Visit website Investor relations

WVE · Wave Life Sciences, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance